Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Grifols S.A. (GRFS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 14,687,459
  • Shares Outstanding, K 682,820
  • Annual Sales, $ 4,482 M
  • Annual Income, $ 603,600 K
  • 36-Month Beta 0.98
  • Price/Sales 3.28
  • Price/Cash Flow 16.08
  • Price/Book 3.72

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.45 +5.18%
on 09/21/17
21.98 -2.14%
on 09/29/17
+0.77 (+3.71%)
since 09/15/17
3-Month
19.92 +7.98%
on 07/27/17
21.98 -2.14%
on 09/29/17
+0.51 (+2.43%)
since 07/17/17
52-Week
14.27 +50.74%
on 10/31/16
22.83 -5.78%
on 06/22/17
+6.40 (+42.36%)
since 10/17/16

Most Recent Stories

More News
Should Value Investors Consider Grifols (GRFS) Stock Now?

Is Grifols (GRFS) a great pick from the value investor's perspective right now? Read on to know more.

GRFS : 21.51 (+0.05%)
3 Pharma/Biotech Sector Bargains for a Healthy Portfolio

The biotech sector has turned around after its dismal performance in 2016 as uncertainty surrounding drug pricing control subsides. A few stocks are however still undervalued, which may gain going ahead....

PDLI : 3.45 (-1.71%)
JAZZ : 140.50 (unch)
GRFS : 21.51 (+0.05%)
GILD : 80.24 (+0.36%)
KITE : 179.99 (+0.11%)
Technical Insights on Biotech Stocks -- Grifols, Halozyme Therapeutics, Illumina, and VIVUS

If you want a Stock Review on GRFS, HALO, ILMN, or VVUS then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Thursday, benchmark US indices were...

ILMN : 206.48 (+0.12%)
VVUS : 0.80 (-3.61%)
GRFS : 21.51 (+0.05%)
HALO : 17.74 (-0.67%)
Grifols Phocus Rx® Pharmacy Workflow Management Solution Now Integrates With Top Hospital Information Systems via HL7 Interfaces

-- Phocus Rx® enhances safety and improves hospital pharmacy workflow efficiencies with real-time electronic data warehousing and preparation history for drug traceability, retrospective reviewing, and...

GRFS : 21.51 (+0.05%)
GRF : 8.30 (+0.30%)
Select American Red Cross Blood Donations Screened for Babesia Parasite Using Grifols' Procleix Babesia Assay Under an Investigational New Drug Protocol

Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, announced today that the American...

GRFS : 21.51 (+0.05%)
GRF : 8.30 (+0.30%)
Grifols adds ID RHD XT diagnostic kit to its molecular portfolio

- Grifols receives CE mark approval for ID RHD XT

GRFS : 21.51 (+0.05%)
Grifols Continues to Strengthen its Diagnostic Division by Launching New Global Testing Services for the Measurement of Biological Drug Levels and Anti-Drug Immune Response in Blood Samples

Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a leading global producer of plasma-derived medicines, and a leader in the development of innovative diagnostic solutions, is expanding its Texas-based...

GRFS : 21.51 (+0.05%)
GRF : 8.30 (+0.30%)
Should Value Investors Consider Grifols (GRFS) Stock Right Now?

Is Grifols a great pick from the value investor's perspective right now? Read on to know more.

GRFS : 21.51 (+0.05%)
Daily Technical Summary Reports on Biotech Stocks -- Illumina, Navidea Biopharma, Grifols, and Intercept Pharma

DailyStockTracker.com today reviews Illumina Inc. (NASDAQ: ILMN), Navidea Biopharmaceuticals Inc (NYSE MKT: NAVB), Grifols S.A. (NASDAQ: GRFS), and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT). According...

ILMN : 206.48 (+0.12%)
GRFS : 21.51 (+0.05%)
NAVB : 0.44 (unch)
ICPT : 67.06 (-0.46%)
Grifols Makes Procleix Zika Virus Assay Available for Screening Blood Donations to Countries Accepting CE Mark

- Grifols strengthens its Procleix portfolio with the CE marking for Procleix Zika Virus Assay

GRFS : 21.51 (+0.05%)
GRF : 8.30 (+0.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More

Business Summary

Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience...

See More

Support & Resistance

2nd Resistance Point 21.73
1st Resistance Point 21.62
Last Price 21.51
1st Support Level 21.32
2nd Support Level 21.13

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart